Article 1 to 10 out of 15 concerning Epigenomics AG
Epigenomics Successfully Completes Larger Clinical Study in Early Lung Cancer Detection(19 Jun 2008) Panel with two biomarkers confirms solid performance in larger blood plasma study Epigenomics AG announced that it successfully completed a larger clinical study in its lung cancer program. The study was run in close collaboration with Prof. Dr. Christian Witt and Dr. Bernd Schmidt at the Charité University Hospital in Berlin, ...
Epigenomics AG Forms Medical Advisory Board for Colorectal Cancer Screening(11 Oct 2007) High-profile board to support Epigenomics in development and commercialization of its colorectal cancer screening test in the U.S. Epigenomics AG announced the formation of its Colorectal Cancer Medical Advisory board and the appointment of its first four members. The board will advise Epigenomics on important aspects of the clinical development and commercialization process of ...
Epigenomics AG: Key patents for cancer testing granted(05 Oct 2007) Epigenomics AG announced that key patents covering Epigenomics' core technology HeavyMethyl® for the sensitive detection of methylated DNA have been granted by the patent authorities in a wide range of market regions including Europe and the ...
Epigenomics AG: strategic in vitro diagnostics partnership with Abbott Molecular(27 Sep 2007) Collaboration focuses on development and global commercialization of a molecular diagnostic test for the early detection of colorectal cancer.Abbott obtains non-exclusive worldwide rights to Epigenomics' proprietary DNA methylation biomarker Septin ...
Epigenomics DNA methylation test successfully detects colorectal cancer in blood(20 Dec 2005) Epigenomics AG announced positive results of a series of large clinical studies, demonstrating that its molecular diagnostic test developed in collaboration with Roche Diagnostics was able to detect colorectal cancer from a standard, non-invasive ...
Epigenomics reports Tamoxifen treatment response test study results inconclusive(01 Nov 2005) Epigenomics AG announced that following the timely completion of a blinded test study for its Tamoxifen treatment response test, the candidate markers could not be independently validated for technical reasons. The Tamoxifen treatment response test ...
Top
